Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of G s α

Thomas J. Gould, Scott P. Bizily, Jan Tokarczyk, Michele P. Kelly, Steven J. Siegel, Stephen J. Kanes, Ted Abel

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Schizophrenia is a complex disorder characterized by wide-ranging cognitive impairments, including deficits in learning as well as sensory gating. The causes of schizophrenia are unknown, but alterations in intracellular G-protein signaling pathways are among the molecular changes documented in patients with schizophrenia. Using the CaMKIIα promoter to drive expression in neurons within the forebrain, we have developed transgenic mice that express a constitutively active form of G s α (G s α*), the G protein that couples receptors such as the D 1 and D 5 dopamine receptors to adenylyl cyclase. We have also generated mice in which the CaMKIIα promoter drives expression of a dominant-negative form of protein kinase A, R(AB). Here, we examine startle responses and prepulse inhibition of the startle reflex (PPI) in these G s α* and R(AB) transgenic mice. G s α* transgenic mice exhibited selective deficits in PPI, without exhibiting alterations in the startle response, whereas no deficit in startle or PPI was found in the R(AB) transgenic mice. Thus, overstimulation of the cAMP/PKA pathway disrupts PPI, but the cAMP/PKA pathway may not be essential for sensorimotor gating. G s α* transgenic mice may provide an animal model of certain endophenotypes of schizophrenia, because of the similarities between them and patients with schizophrenia in G-protein function, hippocampus-dependent learning, and sensorimotor gating.

Original languageEnglish (US)
Pages (from-to)494-501
Number of pages8
JournalNeuropsychopharmacology
Volume29
Issue number3
DOIs
StatePublished - Mar 1 2004

Fingerprint

Sensory Gating
Startle Reflex
Transgenic Mice
Schizophrenia
GTP-Binding Proteins
Calcium-Calmodulin-Dependent Protein Kinase Type 2
Intracellular Signaling Peptides and Proteins
Learning
Endophenotypes
Dopamine Receptors
Prosencephalon
Cyclic AMP-Dependent Protein Kinases
Adenylyl Cyclases
Hippocampus
Animal Models
Neurons

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Gould, Thomas J. ; Bizily, Scott P. ; Tokarczyk, Jan ; Kelly, Michele P. ; Siegel, Steven J. ; Kanes, Stephen J. ; Abel, Ted. / Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of G s α In: Neuropsychopharmacology. 2004 ; Vol. 29, No. 3. pp. 494-501.
@article{3cccdd6ff8c04c51a7cf09a7dc0f0ea5,
title = "Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of G s α",
abstract = "Schizophrenia is a complex disorder characterized by wide-ranging cognitive impairments, including deficits in learning as well as sensory gating. The causes of schizophrenia are unknown, but alterations in intracellular G-protein signaling pathways are among the molecular changes documented in patients with schizophrenia. Using the CaMKIIα promoter to drive expression in neurons within the forebrain, we have developed transgenic mice that express a constitutively active form of G s α (G s α*), the G protein that couples receptors such as the D 1 and D 5 dopamine receptors to adenylyl cyclase. We have also generated mice in which the CaMKIIα promoter drives expression of a dominant-negative form of protein kinase A, R(AB). Here, we examine startle responses and prepulse inhibition of the startle reflex (PPI) in these G s α* and R(AB) transgenic mice. G s α* transgenic mice exhibited selective deficits in PPI, without exhibiting alterations in the startle response, whereas no deficit in startle or PPI was found in the R(AB) transgenic mice. Thus, overstimulation of the cAMP/PKA pathway disrupts PPI, but the cAMP/PKA pathway may not be essential for sensorimotor gating. G s α* transgenic mice may provide an animal model of certain endophenotypes of schizophrenia, because of the similarities between them and patients with schizophrenia in G-protein function, hippocampus-dependent learning, and sensorimotor gating.",
author = "Gould, {Thomas J.} and Bizily, {Scott P.} and Jan Tokarczyk and Kelly, {Michele P.} and Siegel, {Steven J.} and Kanes, {Stephen J.} and Ted Abel",
year = "2004",
month = "3",
day = "1",
doi = "10.1038/sj.npp.1300309",
language = "English (US)",
volume = "29",
pages = "494--501",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "3",

}

Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of G s α . / Gould, Thomas J.; Bizily, Scott P.; Tokarczyk, Jan; Kelly, Michele P.; Siegel, Steven J.; Kanes, Stephen J.; Abel, Ted.

In: Neuropsychopharmacology, Vol. 29, No. 3, 01.03.2004, p. 494-501.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of G s α

AU - Gould, Thomas J.

AU - Bizily, Scott P.

AU - Tokarczyk, Jan

AU - Kelly, Michele P.

AU - Siegel, Steven J.

AU - Kanes, Stephen J.

AU - Abel, Ted

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Schizophrenia is a complex disorder characterized by wide-ranging cognitive impairments, including deficits in learning as well as sensory gating. The causes of schizophrenia are unknown, but alterations in intracellular G-protein signaling pathways are among the molecular changes documented in patients with schizophrenia. Using the CaMKIIα promoter to drive expression in neurons within the forebrain, we have developed transgenic mice that express a constitutively active form of G s α (G s α*), the G protein that couples receptors such as the D 1 and D 5 dopamine receptors to adenylyl cyclase. We have also generated mice in which the CaMKIIα promoter drives expression of a dominant-negative form of protein kinase A, R(AB). Here, we examine startle responses and prepulse inhibition of the startle reflex (PPI) in these G s α* and R(AB) transgenic mice. G s α* transgenic mice exhibited selective deficits in PPI, without exhibiting alterations in the startle response, whereas no deficit in startle or PPI was found in the R(AB) transgenic mice. Thus, overstimulation of the cAMP/PKA pathway disrupts PPI, but the cAMP/PKA pathway may not be essential for sensorimotor gating. G s α* transgenic mice may provide an animal model of certain endophenotypes of schizophrenia, because of the similarities between them and patients with schizophrenia in G-protein function, hippocampus-dependent learning, and sensorimotor gating.

AB - Schizophrenia is a complex disorder characterized by wide-ranging cognitive impairments, including deficits in learning as well as sensory gating. The causes of schizophrenia are unknown, but alterations in intracellular G-protein signaling pathways are among the molecular changes documented in patients with schizophrenia. Using the CaMKIIα promoter to drive expression in neurons within the forebrain, we have developed transgenic mice that express a constitutively active form of G s α (G s α*), the G protein that couples receptors such as the D 1 and D 5 dopamine receptors to adenylyl cyclase. We have also generated mice in which the CaMKIIα promoter drives expression of a dominant-negative form of protein kinase A, R(AB). Here, we examine startle responses and prepulse inhibition of the startle reflex (PPI) in these G s α* and R(AB) transgenic mice. G s α* transgenic mice exhibited selective deficits in PPI, without exhibiting alterations in the startle response, whereas no deficit in startle or PPI was found in the R(AB) transgenic mice. Thus, overstimulation of the cAMP/PKA pathway disrupts PPI, but the cAMP/PKA pathway may not be essential for sensorimotor gating. G s α* transgenic mice may provide an animal model of certain endophenotypes of schizophrenia, because of the similarities between them and patients with schizophrenia in G-protein function, hippocampus-dependent learning, and sensorimotor gating.

UR - http://www.scopus.com/inward/record.url?scp=1642320064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642320064&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1300309

DO - 10.1038/sj.npp.1300309

M3 - Article

VL - 29

SP - 494

EP - 501

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 3

ER -